Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Following two decades of more than 400 clinical trials centered on the “one drug, one target,
one disease” paradigm, there is still no effective disease‐modifying therapy for Alzheimer's …
one disease” paradigm, there is still no effective disease‐modifying therapy for Alzheimer's …
[HTML][HTML] From single target to multitarget/network therapeutics in Alzheimer's therapy
Brain network dysfunction in Alzheimer's disease (AD) involves many proteins (enzymes),
processes and pathways, which overlap and influence one another in AD pathogenesis …
processes and pathways, which overlap and influence one another in AD pathogenesis …
[HTML][HTML] A review of the recent advances in Alzheimer's disease research and the utilization of network biology approaches for prioritizing diagnostics and therapeutics
Alzheimer's disease (AD) is a polygenic multifactorial neurodegenerative disease that, after
decades of research and development, is still without a cure. There are some symptomatic …
decades of research and development, is still without a cure. There are some symptomatic …
Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications …
Because disease-associated microglia (DAM) and disease-associated astrocytes (DAA) are
involved in the pathophysiology of Alzheimer's disease (AD), we systematically identified …
involved in the pathophysiology of Alzheimer's disease (AD), we systematically identified …
[HTML][HTML] Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau
S Rayaprolu, L Higginbotham, P Bagchi… - …, 2021 - nature.com
The repeated failures of amyloid-targeting therapies have challenged our narrow
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …
[HTML][HTML] Most pathways can be related to the pathogenesis of Alzheimer's disease
Alzheimer's disease (AD) is a complex neurodegenerative disorder. The relative contribution
of the numerous underlying functional mechanisms is poorly understood. To …
of the numerous underlying functional mechanisms is poorly understood. To …
[HTML][HTML] Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease
Background Genome-wide association studies (GWAS) have identified numerous
susceptibility loci for Alzheimer's disease (AD). However, utilizing GWAS and multi-omics …
susceptibility loci for Alzheimer's disease (AD). However, utilizing GWAS and multi-omics …
Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets
Alzheimer's disease (AD), the most common form of dementia, is recognized as a
heterogeneous disease with diverse pathophysiologic mechanisms. In this study, we …
heterogeneous disease with diverse pathophysiologic mechanisms. In this study, we …
[HTML][HTML] Artificial intelligence for drug discovery and development in Alzheimer's disease
The complex molecular mechanism and pathophysiology of Alzheimer's disease (AD) limits
the development of effective therapeutics or prevention strategies. Artificial Intelligence (AI) …
the development of effective therapeutics or prevention strategies. Artificial Intelligence (AI) …
Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's …
We developed an endophenotype disease module-based methodology for Alzheimer's
disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier …
disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier …